Facilitating T1 Translational Aging Research: Preclinical and Early Phase Human Studies (UG3/UH3 Clinical Trial Optional)
The summary for the Facilitating T1 Translational Aging Research: Preclinical and Early Phase Human Studies (UG3/UH3 Clinical Trial Optional) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Facilitating T1 Translational Aging Research: Preclinical and Early Phase Human Studies (UG3/UH3 Clinical Trial Optional): This Notice of Funding Opportunity (NOFO) from the National Institute on Aging (NIA) invites applications on T1 translational aging research (i.e., bench to bedside) which focus on advancing new therapeutics from preclinical stages to first-in-human (FIH) trials for aging-related conditions such as sarcopenia, heart failure with preserved ejection fraction (HFpEF), and deficits such as immunosenescence. The NOFO will specifically support two categories of milestone-driven projects: 1) traditional de novo drug development (i.e., new chemical/molecular entities) with three specific entry points to the translational pipeline (i.e., screening through preclinical validation, hit to lead through IND, or late-stage preclinical development through FIH studies), and 2) data-driven computational drug repurposing strategies with subsequent validation of predictions and generation of proof-of-concept data in pertinent animal models and/or in human in vitro studies.For the purposes of this NOFO, drug repurposing (also known as drug repositioning, reprofiling or re-tasking) refers to approaches for identifying alternative uses for FDA-approved drugs or investigational therapeutics which are beyond the scope of the original intended clinical indication. The types and scale of proposed translational research activities in the projects are anticipated to vary and will depend on whether the project focuses on traditional drug development pathways or involves drug repurposing. The UG3 phase of this NOFO will support T1 translational research planning activities and preliminary studies. Transition to the UH3 phase (based on achievement of UG3 milestones proposed by the investigators) will enable more comprehensive pharmacology and/or toxicology evaluations of the proposed therapeutics, including replication studies to confirm preliminary findings or experimental validation of predictive models.
| Federal Grant Title: | Facilitating T1 Translational Aging Research: Preclinical and Early Phase Human Studies (UG3/UH3 Clinical Trial Optional) |
| Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
| Grant Categories: | Health |
| Type of Opportunity: | Discretionary |
| Funding Opportunity Number: | RFA-AG-25-027 |
| Type of Funding: | Cooperative Agreement |
| CFDA Numbers: | 93.866 |
| CFDA Descriptions: | Information not provided |
| Current Application Deadline: | January 10th, 2025 |
| Original Application Deadline: | January 10th, 2025 |
| Posted Date: | October 28th, 2024 |
| Creation Date: | October 28th, 2024 |
| Archive Date: | February 15th, 2025 |
| Total Program Funding: | |
| Maximum Federal Grant Award: | |
| Minimum Federal Grant Award: | |
| Expected Number of Awards: | |
| Cost Sharing or Matching: | No |
| Last Updated: | October 28th, 2024 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
- Link to Full Grant Announcement
- https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-027.html
- Grant Announcement Contact
- NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. - Similar Government Grants
- • Aging Research Dissertation Awards to Promote Diversity (R36 Clinical Trial Not Allowed)
- • Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R...
- • Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Relate...
- • NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)
- • NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)
- • Technological Enhancements and Archiving for Surveys of the Elderly: SBIR (R43/44) Initiat...
- • Technological Enhancements and Archiving for Surveys of the Elderly: STTR (R41/42) Initiat...
- • Technology and Aging: NIA Small Business Technology Transfer Program Initiative (STTR [R41...
- More Grants from the National Institutes of Health
- • Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
- • Alcohol Health Services Research (R01 Clinical Trial Optional)
- • Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)
- • Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Re...
- • Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the...